STRATA Skin Sciences, Inc. (SSKN) Q2 2025 Earnings Call Transcript

Published in Science and Technology on Wednesday, August 13th 2025 at 22:47 GMT by Seeking Alpha
^{🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source}

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ETCompany ParticipantsDolev Rafaeli - President, CEO &...

In-Depth Summary of Strata Skin Sciences Inc. (SSKN) Q2 2025 Earnings Call

Strata Skin Sciences Inc., a medical technology company specializing in innovative solutions for dermatology, held its second-quarter 2025 earnings conference call on August 14, 2025. The call featured key executives, including Dr. Dolev Rafaeli, the company's Chief Executive Officer, and Christopher Lesovitz, the Chief Financial Officer. The discussion provided a comprehensive overview of the company's financial performance, operational achievements, strategic initiatives, and forward-looking guidance, amid a challenging yet promising landscape in the dermatology sector.

Dr. Rafaeli opened the call by highlighting the company's core mission: to deliver cutting-edge treatments for skin conditions like psoriasis, vitiligo, and atopic dermatitis through its flagship XTRAC excimer laser system and the TheraClear acne treatment device. He emphasized Strata's unique direct-to-consumer (DTC) marketing approach, which has been instrumental in driving patient awareness and clinic utilization. Rafaeli noted that the quarter marked continued progress in expanding the installed base of XTRAC devices, with a focus on recurring revenue streams from per-treatment fees. He also touched on the integration of recent acquisitions and partnerships that are enhancing the company's product portfolio.

Financially, the quarter showed mixed results but with positive underlying trends. Total revenue for Q2 2025 came in at approximately $8.5 million, representing a slight decline of about 3% year-over-year, primarily attributed to seasonal fluctuations in dermatology procedures and some reimbursement challenges. However, Rafaeli pointed out that this figure masked robust growth in key areas. Recurring revenues, which form the backbone of Strata's business model, increased by 5% to $6.2 million, driven by higher utilization rates of XTRAC systems. The company placed 15 new XTRAC devices during the quarter, bringing the total installed base to over 1,000 units across the U.S. and select international markets. International revenues saw a notable uptick, growing 12% to $1.1 million, fueled by expanded distribution agreements in Asia and Europe.

Lesovitz delved deeper into the financials, providing a breakdown of expenses and margins. Gross margins improved to 62% from 59% in the prior-year quarter, thanks to operational efficiencies and better supply chain management. Operating expenses were $7.2 million, up modestly due to increased marketing spend on DTC campaigns and R&D investments in next-generation devices. Net loss narrowed to $1.8 million, or $0.05 per share, compared to $2.1 million, or $0.06 per share, in Q2 2024. Cash and cash equivalents stood at $9.4 million as of June 30, 2025, with no significant debt maturities on the horizon. Lesovitz highlighted the company's focus on cash flow positivity, noting that adjusted EBITDA was positive at $0.5 million, a turnaround from a slight loss in the previous quarter.

Operationally, Rafaeli discussed several strategic highlights. The TheraClear X device, acquired in 2023, is gaining traction with dermatologists for its non-invasive acne treatment capabilities. The company reported a 20% increase in TheraClear placements, with 25 new units deployed in Q2. Rafaeli elaborated on the success of the DTC marketing strategy, which includes targeted digital campaigns and partnerships with influencers and patient advocacy groups. This has led to a 15% rise in patient inquiries and a corresponding boost in treatment volumes. Additionally, Strata is advancing its pipeline with clinical trials for expanded indications of the XTRAC system, including potential applications in scar reduction and other inflammatory skin conditions.

Looking ahead, the executives expressed optimism for the second half of 2025 and beyond. Full-year revenue guidance was reaffirmed at $35 million to $37 million, implying low-to-mid single-digit growth. This outlook is supported by anticipated increases in device placements, higher utilization rates, and international expansion. Rafaeli mentioned plans to enter new markets in Latin America and strengthen ties with key opinion leaders in dermatology. On the reimbursement front, the company is actively engaging with payers to secure better coverage for XTRAC treatments, which could unlock additional revenue potential. Lesovitz added that cost-control measures, including supply chain optimizations, are expected to further enhance margins, targeting 65% gross margins by year-end.

The call also addressed potential risks and challenges. Rafaeli acknowledged ongoing macroeconomic pressures, such as inflation impacting clinic budgets and patient out-of-pocket costs. There's also competition from emerging therapies in the psoriasis space, including biologics and topical treatments. However, he stressed Strata's competitive edge through its non-pharmacological, office-based solutions that offer convenience and efficacy without systemic side effects. The company is monitoring regulatory developments, particularly FDA clearances for device enhancements.

In the Q&A portion, analysts probed deeper into specific metrics. One question focused on the average revenue per XTRAC device, which Rafaeli reported at around $25,000 annually, up from $23,000 last year, thanks to improved utilization. Another inquiry addressed the impact of telehealth integrations, with Rafaeli noting that virtual consultations are boosting patient access and could add 10-15% to treatment volumes. On international growth, Lesovitz explained that partnerships in South Korea and Japan are performing well, with expectations for double-digit revenue contributions in 2026. Analysts also asked about M&A plans; Rafaeli indicated that while the company is open to accretive acquisitions, the current focus is on organic growth and integrating existing assets.

Overall, the earnings call painted a picture of a resilient company navigating a dynamic healthcare environment. Strata Skin Sciences appears poised for steady growth, leveraging its innovative technologies and patient-centric strategies. Investors were encouraged by the emphasis on recurring revenues and margin improvements, which provide a stable foundation amid uncertainties. As the dermatology market continues to evolve with rising incidences of skin disorders, Strata's position as a leader in laser-based therapies could drive long-term value. The call concluded with Rafaeli reiterating the company's commitment to enhancing shareholder value through disciplined execution and innovation.

(This summary captures the essence of the transcript, distilling key financial data, strategic updates, and executive commentary into a cohesive narrative for stakeholders and observers in the medical technology sector. Word count: 928)

Read the Full Seeking Alpha Article at:
[ https://seekingalpha.com/article/4813396-strata-skin-sciences-inc-sskn-q2-2025-earnings-call-transcript ]